Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Operating income | -$21.6M | -$42.3M | -$69.6M | -$56.8M | -$38.1M |
| Net income | -$21.5M | -$41.0M | -$64.7M | -$51.3M | -$35.2M |
| EPS (diluted) | -$10.64 | -$2.79 | -$2.74 | -$1.72 | -$1.16 |
| Fiscal year | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Operating cash flow | -$20.5M | -$33.5M | -$53.3M | -$49.3M | -$29.8M |
| Fiscal year | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Cash & equivalents | $12.1M | $27.2M | $15.6M | $21.4M | $19.9M |
| Total assets | $65.3M | $103M | $139M | $92.1M | $62.0M |
| Total liabilities | $3.41M | $7.19M | $14.0M | $10.2M | $8.89M |
| Shareholders' equity | -$47.4M | $95.4M | $125M | $81.8M | $53.1M |
| Retained earnings | -$47.4M | -$89.7M | -$154M | -$206M | -$241M |
| Shares (wtd avg diluted) | 2.64M | 15.3M | 23.6M | 29.8M | 30.2M |
Every figure is extracted from AN2 Therapeutics, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.